Physiopathology: Coughing is the sudden expulsion of air from the Upper respiratory tract (URT) to block the entry of contaminants in the lower RT & to avoid pulmonary infection. When the URT surface is damaged due to an infection (viral or bacterial), irritation or smoking, the throat mucosal cells die and produce cellular debris. Damaged mucosal surface creates a favorable ground for the growth of microorganisms leading to inflammation, liberation of cytokines (inflammatory proteins), leading to irritation, pain & coughing. In dry cough, the throat surface is dry with no phlegm or mucus & the throat mucosa is highly damaged. In wet cough, throat surface is mucoid, sticky containing many virus particles on an inflamed mucosa.

An Ideal treatment: Because cough is a multifactorial condition, simultaneously involving viral infection, cellular damage, strong bacterial growth, & topical inflammation, an effective treatment should act on all these factors at once, otherwise it can’t be effective. It should also be non-irritant, fast acting & safe.

Currently available treatments: All the currently available treatments are symptomatic a mono-target such as such as the expectorants (ipecacuanha), mucolytic (acetylcystine), antitussives (centrally acting such as opioids, codeines, morphine), non-opioids (such as anticholinergic benzonatate), anti-inflammatory, & antibiotics acting on one of the parameters involved in coughing. These are symptomatic drugs and have multiple side-effects such as addiction, nausea, drowsiness, headache, sedation. They don’t improve throat dryness, inflammation, virus load, and therefore they don’t allow natural healing to occur.


1.Cleaning the cough & the contaminants mechanically:

After 20-years of R&D, VITROBIO discovered and patented a viscous liquid, 18 times more osmotically active than sea water yet NON-IRRITANT (VB-Gy – PCT/FR99/01340). For a prolonged activity, VB-Gy was rendered filmogen using specific plant polymers (PCT/EP2013/061835). When applied on the throat surface, this hypertonic film attracts hypotonic liquid & generates a strong outward liquid flow. Along with protecting the throat surface, the liquid flow drains the bacteria & other contaminants thereby supressing the cough reflex. Simultaneously, continuous liquid flow dilutes & removes the cough and  keeps the throat surface hydrated. VB-Gy has three key functions: Protective Antibacterial Cleaning.

2.Introducing anti-viral & anti-inflammatory properties in VB-Gy cough spray:

Virus envelops contain proteins such as the H1N1 (hemagglutinin & neuraminidase) glycoproteins on influenza virus, and VP-1,2, 3, & 4 proteins on rhinovirus, which help virus attachment & entry into the cells. Currently there is no topical anti-viral drug to stop virus attachment or entry into the cells. Virus enveloppe contains proteins.

Inflammation is caused due to topical presence of multiple pro-inflammatory cytokines: INF- ˠ, TNF-α, IL-1β, IL-4 and IL-5. Currently there are no drugs to selectively block these cytokines. Inflammatory cytokines are proteins.

Being proteins, we used selected « protein inhibitor polymers » to block instantly the virus & inflammatory proteins. These polymers are incorporated in filmogen VB-Gy cough spray.

The polymeric compositions used to treat dry or wet coughs can block up to 98% virus & up to 75% selected inflammatory cytokines within 5-minutes.

These are the 1st topical protease inhibitor treatments in the world.

Clinical Efficacy:

A 14-day, randomized, placebo controlled, double blind, efficacy and safety study was conducted on 37 dry cough treated v/s 17 saline solution treated comparator patients for maximum 14-days. Cough related parameters were evaluated on days 1, 2, 3, 6, 9, 12, & 14. Compared to the comparator product, test product triggered an instant & strong reduction in mean scores of cough severity & frequency. A strong reduction in throat pain irritation, swelling, & redness along with a remarkable improvement in Leicester cough questionnaire was recorded. No drug-related undesired events were noticed.

Full trial published in J. Clinical Trials, Shrivastava et al., 2017, 7:4: DOI: 10.4172/2167-0870.1000318